Tagged with

Genetic Immunity Genetic Immunity has been founded in 1998. What drove you to set up the company at that time? J.L: To understand the context better, I first need to give a little bit of background on myself. I left for Germany right after I finished university in Hungary, where I was…

Increasing integration with the world economy and accession to the European Union (EU) in 2007 have been key pillars in taking the growth potential of Romania’s pharmaceutical market to greater heights. Valued at $3.3 billion, Romania was recently labelled an IMS Tier 3 category of ‘Fast Followers’ among the world’s…

A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has had a detrimental effect on generics companies in the Netherlands. How has fallout from the preference policy revolutionized Actavis’s operations…

Chiltern UK Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as the UK? I am confident that the UK will remain a key region for research and innovation for the global…

Russia CONSULTING You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind the creation of Russia Consulting, and the main growth drivers contributing to its development? When I was a student, I…

When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did for the generics market. Are you as optimistic? Biogen Idec has been very close to ANVISA and part of the…

Quintiles Russia The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in Russia, after setting up a local legal entity for the delivery of commercial operations. What is the nature of this…

Quintiles Russia The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of its first commercial project in Russia, after setting up a local legal entity for the delivery of commercial operations. What…

EGIS Romania You have been general manager of this affiliate for three years after a previous tenure as general manager of Leo Pharma here and in Bulgaria. The end of 2008 through 2010 were certainly not the easiest years for pharmaceutical companies. What was the business environment like when you first came…

GSK Pharma CIS GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s portfolio into novel areas and putting greater emphasis on emerging markets. How is the Russian affiliate contributing to the realization…

Invar The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in Russia immediately after the fall of the Soviet Union. This company began as a regional investment & consulting business—why did…

Goltsblat BLP Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale behind the creation of this firm and why Goltsblat BLP is interesting for the market? There was a split amongst…